AG˹ٷ

STOCK TITAN

[Form 4] Biogen Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Biogen Inc. (BIIB) � Form 4 insider filing

Director Jesus B. Mantas reported one transaction dated 06/17/2025. The filing shows an "A" transaction code (acquisition) for 2,370 shares of Biogen common stock at a stated price of $0.00, indicating a stock award or grant. After this transaction, the director’s direct beneficial ownership increases to 9,758 shares. No derivative security transactions were reported, and there are no sales or dispositions disclosed in the filing.

The form was signed by an attorney-in-fact on 06/18/2025. No other insiders or joint filers are involved, and there is no indication that the reporting person is no longer subject to Section 16.

Biogen Inc. (BIIB) � Comunicazione interna Form 4

Il direttore Jesus B. Mantas ha riportato una transazione datata 17/06/2025. La comunicazione indica un codice transazione "A" (acquisizione) per 2.370 azioni ordinarie di Biogen a un prezzo dichiarato di $0,00, segnalando un premio o una concessione azionaria. Dopo questa operazione, la posizione diretta di proprietà effettiva del direttore sale a 9.758 azioni. Non sono state segnalate transazioni su strumenti derivati, né vendite o cessioni nel documento.

Il modulo è stato firmato da un procuratore il 18/06/2025. Non risultano altri insider o co-dichiaranti coinvolti, né indicazioni che la persona segnalante non sia più soggetta alla Sezione 16.

Biogen Inc. (BIIB) � Presentación interna Formulario 4

El director Jesus B. Mantas reportó una transacción fechada el 17/06/2025. La presentación muestra un código de transacción "A" (adquisición) por 2,370 acciones comunes de Biogen a un precio declarado de $0.00, indicando una concesión o premio en acciones. Tras esta transacción, la propiedad directa beneficiaria del director aumenta a 9,758 acciones. No se reportaron transacciones con valores derivados ni ventas o disposiciones en la presentación.

El formulario fue firmado por un apoderado el 18/06/2025. No hay otros insiders o co-reportantes involucrados, ni indicios de que la persona reportante haya dejado de estar sujeta a la Sección 16.

Biogen Inc. (BIIB) � 내부� 보고� Form 4

이사 Jesus B. Mantas2025� 6� 17�� 거래 하나� 보고했습니다. 보고서에� "A" 거래 코드(취득)� Biogen 보통� 2,370�� 명시 갶� $0.00� 취득� 것으� 나타�, 주식 보상 또는 부여를 의미합니�. � 거래 �, 이사� 직접 실질 소유�9,758�� 증갶했습니�. 파생상품 거래� 보고되지 않았으며, 매도� 처분 내역� 없습니다.

해당 양식읶 2025� 6� 18�� 대리인� 서명했습니다. 다른 내부자나 공동 신고자는 없으�, 보고자갶� � 이상 섹션 16� 적용� 받지 않는다는 징후� 없습니다.

Biogen Inc. (BIIB) � Déclaration interne Formulaire 4

Le directeur Jesus B. Mantas a déclaré une transaction datée du 17/06/2025. La déclaration indique un code de transaction "A" (acquisition) pour 2 370 actions ordinaires de Biogen à un prix déclaré de 0,00 $, ce qui correspond à une attribution ou une attribution d’actions. Après cette transaction, la possession directe bénéficiaire du directeur augmente à 9 758 actions. Aucune transaction sur titres dérivés n’a été signalée, et aucune vente ou cession n’est mentionnée dans la déclaration.

Le formulaire a été signé par un mandataire le 18/06/2025. Aucun autre initié ou déclarant conjoint n’est impliqué, et rien n’indique que la personne déclarant ne soit plus soumise à la Section 16.

Biogen Inc. (BIIB) � Form 4 Insider-Meldung

Direktor Jesus B. Mantas meldete eine Transaktion vom 17.06.2025. Die Meldung zeigt einen "A" Transaktionscode (Erwerb) für 2.370 Aktien der Biogen-Stammaktien zu einem angegebenen Preis von $0,00, was auf eine Aktienzuteilung oder -gewährung hindeutet. Nach dieser Transaktion erhöht sich das direkte wirtschaftliche Eigentum des Direktors auf 9.758 Aktien. Es wurden keine Derivatgeschäfte gemeldet, und es gibt keine Verkäufe oder Veräußerungen in der Meldung.

Das Formular wurde am 18.06.2025 von einem Bevollmächtigten unterzeichnet. Es sind keine weiteren Insider oder gemeinsame Melder beteiligt, und es gibt keinen Hinweis darauf, dass die meldende Person nicht mehr der Sektion 16 unterliegt.

Positive
  • Insider acquisition: Director Jesus B. Mantas acquired 2,370 BIIB shares, increasing direct ownership to 9,758 shares.
  • No insider sales: The filing contains only acquisitions, signaling continued confidence and alignment.
Negative
  • None.

Insights

TL;DR: Small insider stock award—positive alignment, limited market impact.

The acquisition of 2,370 BIIB shares for no cash consideration signals routine equity compensation for Director Jesus B. Mantas. Although the dollar value is modest relative to Biogen’s market capitalization, any additional insider ownership marginally aligns board interests with shareholders. No sales were reported, which avoids negative optics. From a trading perspective, the event is unlikely to move the stock, but it adds a slice of constructive sentiment around governance and insider commitment.

TL;DR: Routine director grant, governance-neutral, mildly positive for alignment.

Form 4 shows a straightforward equity grant under code "A"—commonly restricted stock—consistent with standard board compensation programs. The post-grant holding of 9,758 shares places the director above the typical minimum ownership guidelines many S&P 500 boards set, supporting best-practice alignment. No dispositions, pledges, or 10b5-1 plan notations were disclosed, reducing potential governance red flags. Overall, the filing is standard but modestly positive for ownership alignment.

Biogen Inc. (BIIB) � Comunicazione interna Form 4

Il direttore Jesus B. Mantas ha riportato una transazione datata 17/06/2025. La comunicazione indica un codice transazione "A" (acquisizione) per 2.370 azioni ordinarie di Biogen a un prezzo dichiarato di $0,00, segnalando un premio o una concessione azionaria. Dopo questa operazione, la posizione diretta di proprietà effettiva del direttore sale a 9.758 azioni. Non sono state segnalate transazioni su strumenti derivati, né vendite o cessioni nel documento.

Il modulo è stato firmato da un procuratore il 18/06/2025. Non risultano altri insider o co-dichiaranti coinvolti, né indicazioni che la persona segnalante non sia più soggetta alla Sezione 16.

Biogen Inc. (BIIB) � Presentación interna Formulario 4

El director Jesus B. Mantas reportó una transacción fechada el 17/06/2025. La presentación muestra un código de transacción "A" (adquisición) por 2,370 acciones comunes de Biogen a un precio declarado de $0.00, indicando una concesión o premio en acciones. Tras esta transacción, la propiedad directa beneficiaria del director aumenta a 9,758 acciones. No se reportaron transacciones con valores derivados ni ventas o disposiciones en la presentación.

El formulario fue firmado por un apoderado el 18/06/2025. No hay otros insiders o co-reportantes involucrados, ni indicios de que la persona reportante haya dejado de estar sujeta a la Sección 16.

Biogen Inc. (BIIB) � 내부� 보고� Form 4

이사 Jesus B. Mantas2025� 6� 17�� 거래 하나� 보고했습니다. 보고서에� "A" 거래 코드(취득)� Biogen 보통� 2,370�� 명시 갶� $0.00� 취득� 것으� 나타�, 주식 보상 또는 부여를 의미합니�. � 거래 �, 이사� 직접 실질 소유�9,758�� 증갶했습니�. 파생상품 거래� 보고되지 않았으며, 매도� 처분 내역� 없습니다.

해당 양식읶 2025� 6� 18�� 대리인� 서명했습니다. 다른 내부자나 공동 신고자는 없으�, 보고자갶� � 이상 섹션 16� 적용� 받지 않는다는 징후� 없습니다.

Biogen Inc. (BIIB) � Déclaration interne Formulaire 4

Le directeur Jesus B. Mantas a déclaré une transaction datée du 17/06/2025. La déclaration indique un code de transaction "A" (acquisition) pour 2 370 actions ordinaires de Biogen à un prix déclaré de 0,00 $, ce qui correspond à une attribution ou une attribution d’actions. Après cette transaction, la possession directe bénéficiaire du directeur augmente à 9 758 actions. Aucune transaction sur titres dérivés n’a été signalée, et aucune vente ou cession n’est mentionnée dans la déclaration.

Le formulaire a été signé par un mandataire le 18/06/2025. Aucun autre initié ou déclarant conjoint n’est impliqué, et rien n’indique que la personne déclarant ne soit plus soumise à la Section 16.

Biogen Inc. (BIIB) � Form 4 Insider-Meldung

Direktor Jesus B. Mantas meldete eine Transaktion vom 17.06.2025. Die Meldung zeigt einen "A" Transaktionscode (Erwerb) für 2.370 Aktien der Biogen-Stammaktien zu einem angegebenen Preis von $0,00, was auf eine Aktienzuteilung oder -gewährung hindeutet. Nach dieser Transaktion erhöht sich das direkte wirtschaftliche Eigentum des Direktors auf 9.758 Aktien. Es wurden keine Derivatgeschäfte gemeldet, und es gibt keine Verkäufe oder Veräußerungen in der Meldung.

Das Formular wurde am 18.06.2025 von einem Bevollmächtigten unterzeichnet. Es sind keine weiteren Insider oder gemeinsame Melder beteiligt, und es gibt keinen Hinweis darauf, dass die meldende Person nicht mehr der Sektion 16 unterliegt.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mantas Jesus B

(Last) (First) (Middle)
BIOGEN INC.
225 BINNEY ST.

(Street)
CAMBRIDGE MA 02142

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/17/2025 A 2,370 A $0 9,758 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Wendell Taylor, Attorney in Fact for Jesus B. Mantas 06/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Biogen (BIIB) shares did Director Jesus B. Mantas acquire?

2,370 shares were acquired on 06/17/2025.

What was the purchase price for the acquired BIIB shares?

The Form 4 lists a price of $0.00, indicating a stock grant or award.

What is the director’s total BIIB share ownership after the transaction?

Jesus B. Mantas now beneficially owns 9,758 shares directly.

Were any BIIB shares sold in this Form 4 filing?

No. The filing reports no dispositions; only an acquisition is shown.

Does the Form 4 mention any 10b5-1 trading plan?

The form provides a checkbox but does not indicate that the transaction was executed under a 10b5-1 plan.
Biogen Inc

NASDAQ:BIIB

BIIB Rankings

BIIB Latest News

BIIB Latest SEC Filings

BIIB Stock Data

18.65B
146.22M
0.21%
94.46%
2.54%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
United States
CAMBRIDGE